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Background: After several exploratory and confirmatory clinical trials, the intralesional administration of
human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced
diabetic foot ulcers (DFU). The aim of this work was to evaluate the effectiveness and safety of this
procedure in medical practice.
Methods: A prospective, post-marketing active pharmacosurveillance was conducted in 41 hospitals and
19 primary care polyclinics. Patients with DFU received hrEGF, 25 or 75 μg, intralesionally 3 times per
week until complete granulation of the ulcer or 8 weeks maximum, adjuvant to standard wound care.
Outcomes measured were complete granulation, amputations, and adverse events (AE) during treatment;
complete lesion re-epithelization and relapses in follow-up (median: 1.2; maximum 4.2 years).
Results: The study included 1788 patients with 1835 DFU (81% Wagner’s grades 3 or 4; 43% ischemic)
treated from May 2007 to April 2010. Complete granulation was observed in 76% of the ulcers in
5 weeks (median). Ulcer non-ischemic etiology (OR: 3.6; 95% CI: 2.8-4.7) and age (1.02; 1.01-1.03, for each
younger year) were the main variables with influence on this outcome. During treatment, 220 (12%)
amputations (171 major) were required in 214 patients, mostly in ischemic or Wagner’s grade 3 to 5
ulcers. Re-epithelization was documented in 61% of the 1659 followed-up cases; 5% relapsed per year.
AE (4171) were reported in 47% of the subjects. Mild or moderate local pain and burning sensation,
shivering and chills, were 87% of the events. Serious events, not related to treatment, occurred in 1.7% of
the patients.
Conclusions: The favorable benefit/risk balance, confirms the beneficial clinical profile of intralesional
hrEGF in the treatment of DFUs.
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Pharmacovigilance and post-marketing studies are key ele-
ments to monitor the safety and effectiveness of approved
drugs. They are excellent scenarios to confirm and extend
the safety profile and efficacy data acquired in previous
clinical trials.
Products for the treatment of diabetic foot ulcers (DFU)
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reproduction in any medium, provided the oradvanced and/or ischemic lesions [1]. Necrotic tissue, sep-
sis, inflammation and wound proteases impair the effect-
ive distribution of the active pharmaceutical ingredients
when they are administered in topically [2].
A new procedure has been recently developed for the
treatment of these advanced DFU based on the intra-
lesional infiltration of recombinant, human epidermal
growth factor (rhEGF) as a lyophilized formulation under
the brand name Heberprot-P®. The rationale of this pro-
cedure has been published and reviewed recently [2,3].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been successfully completed with this product in
patients suffering from advanced DFUs with potential
amputation risk (reviewed in ref. 3). These trials demon-
strated that the intralesional administration of rhEGF ac-
celerates the wound healing process. The generation of
useful granulation tissue on the ulcer bed facilitated its
closure by either second intention or a skin graft. The
product’s safety profile was acceptable and the benefit-
risk analysis of its use yielded a largely favorable balance.
These results granted the approval by the Cuban Regula-
tory Authority (CECMED).
In April 2007 this treatment was included in the country’s
Basic Drugs List and its use was extended to all Angiology
services, firstly in the secondary healthcare level (hospitals)
and subsequently in the primary level (polyclinics).
At the same time, postmarketing active surveillance
was initiated in order to evaluate the effectiveness and
safety of the drug in the current medical practice. This
article reports the first results of this surveillance.
Methods
Design and participants
A multicenter, prospective, intensive, post-marketing sur-
veillance was conducted on patients treated from May
2007 to April 2010; follow-up extended to December
2011. The study was coordinated by the Center for the
Development of Pharmacoepidemiology (CDF) from the
Cuban Ministry of Health and its national network. There
were 41 participating hospitals from the 15 Cuban prov-
inces and 19 polyclinics from 7 provinces.
Patients, more than 18 years-old, suffering from 1 cm2
or larger DFUs were prescribed with rhEGF and included.
The indication comprised Wagner’s [8] grades 3 and 4
DFU, but some patients with grades 1, 2, and 5 were in-
cluded, under off-label use according to the physicians’ de-
cision. Patients with diabetic coma, uncontrolled heart,
renal or liver disease, history or suspicion of malignancy,
pregnancy or breastfeeding were not treated. Prescription
was part of the patient’s regular care, not induced by the
present work. The protocol was approved by the CDF
Institutional Review Board. The confidentiality of the
patients’ personal data was preserved.
Lesion etiology was classified as ischemic or not. When
the ankle/brachial index (ABI) was available, patients with
values below 0.75 were considered ischemic, following the
same criterion used in the clinical trials. Otherwise, clinical
signs of ischemia such as absence of pulses (femoral-pop-
liteal, tibial or distal), intermittent claudication, pain, local
atrophy, coldness, and hair loss were taken into account
for this classification.
Since it was not feasible to standardize the ulcer size
measurement among so many clinical sites, lesion
extension-location was considered in three categories:(i) simple, if the ulcer covered only one region of the
foot (toes, dorsum, sole, internal edge, external edge,
except calcaneus); (ii) complex, if the extension of the
ulcer comprised several regions but not the heel, and
(iii) calcaneal if this region was involved.
Intervention
The treatment was as in-patients, although ambulatory
care was allowed if the subject could attend the treatment
visits. The standard care included the patient’s metabolic
control, lesion area sanitation and systematic cures, sharp
debridement of the necrotic or infected tissue with minor
amputation of the affected zones if necessary, and moist
gauze dressing. Wide spectrum antimicrobial drugs were
prescribed in patients exhibiting local clinical signs of in-
fection. Pressure off-loading of the affected zones was
recommended as well.
The product (Heberprot-P®, Heber Biotec, Havana) is ly-
ophilized, containing 75 or 25 μg of rhEGF per vial, to be
dissolved with 5 ml of water for injection. In every visit
this volume was distributed throughout the lesion in 0.5–
1 ml injections. The solution was injected first into the
dermo-epidermal junction at equidistant points all over
the lesion contours and then downward into the wound
bottom to ensure a uniform distribution. The needle was
changed for each puncture. The product label indicates in-
jections 3 times per week (tpw) on alternate days. How-
ever, in some cases the physicians decided to modify the
schedule to daily, twice or once per week. A treatment
cycle continued until complete granulation was achieved,
lesion closed by autografting or 8 weeks maximum.
The rhEGF dose (25 μg or 75 μg) was selected according
to the label (25 μg in ulcers smaller than 20 cm2 and non-
ischemic), but the choice was also determined by each phy-
sician’s criteria, his/her experience with this product, and
the availability of either drug presentation in the healthcare
unit at a certain moment.
Outcomes and measurement methods
The main effectiveness variable was lesion complete granu-
lation, evaluated by direct visual inspection. It was defined
as productive material, able to mediate the complete lesion
closure by second intention or an autologous skin graft.
Macroscopically, it was characterized by the presence of
reddish, diffused, dispersed and lustrous miliary granular
formations that bleed easily after manipulation.
Secondary outcomes were time-to-complete granula-
tion, need for amputation and its type during treatment.
During the follow-up period wound closure (complete
re-epithelization), relapses, and patient’s survival were
evaluated.
The variables used to evaluate safety were the adverse
events (AE) during the treatment period, considering the
type of event, organ and system affected [9], its seriousness
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done according to the World Health Organization (WHO)
algorithm [10] only for serious adverse events (SAE) by
the provincial pharmaco-epidemiologists and a consulting
multidisciplinary team created ad hoc for this purpose. SAE
reported were included in the Cuban Pharmacosurveillance
System Database, which guarantees the absence of dupli-
cated data when processing reports received from different
sources.
Information was gathered by the physicians in case report
forms (CRF) which covered the in-patient treatment period.
Patients’ final outcome was collected in a further follow-up
visit, done by the hospital or municipality pharmaco-
epidemiology staff, scheduled annually. Emphasis was
placed on the training of the personnel in all aspects related
to the drug safety evaluation.
Deaths during treatment were further investigated by re-
view of the clinical records and, if necropsy was performed,
its report. Causes of death were taken from the death cer-
tificates, coded according to the International Classification
of Disease-10.
The occurrence of any type of cancer was actively in-
vestigated through: (i) direct interview to the patient in
the follow-up visits; (ii) cross-search in the National
Cancer Registry (NCR), or (iii) findings in the National
Mortality Registry. The latter cross search was also use-
ful for the identification and confirmation of follow-up
period deceases.
Statistical analyses
One patient could be treated more than once for the same
or a different lesion at different moments. Then the ex-
perimental unit considered was the treatment cycle, since
each of them generated one CRF. Short term AE were
evaluated on this basis. The lesion was the unit taken into
account for the analyses of granulation, amputations,
healing, and relapses. Survival and long term AE were
done on patient basis.
The statistical treatment of the data was conducted with
the PASW 18.0 software. Measures of central tendency
and dispersion such as mean, median, standard deviation
(SD), 95% CI, quartile range (QR), minimal and maximal
values, were calculated to describe quantitative variables.
Graphical normality analysis (QQPlot) and Kolmogorov-
Smirnov test for goodness of fit were applied. The chi-
square values were calculated to evaluate dependency
among qualitative variables. Time variables were estimated
using Kaplan-Meier plots and compared with the log-rank
test. Logistic or Cox regression models were adjusted to
assess the influence of control variables on the outcomes.
For the variable-association analyses only the results from
the first treatment cycle on each patient were taken into
account to avoid considering non-independent observa-
tions. Safety related variables were subjected to descriptivestatistics. A Bayesian approach was used for the benefit-
risk ratio analysis.
Results
Characteristics of the subjects
CRFs were available from 1788 subjects bearing 1835
DFU. This population represents approximately 80% of all
the DFU patients treated with rhEGF in the study period,
according to weekly reports received at CDF. Of them,
1676 (93.7%), were seen in hospitals and 112 (6.3%) in
polyclinics. Most of the patients (1729; 96.7%) received
one treatment cycle; 56 (3.1%) were given two cycles; four
of them simultaneously on two different lesions and 3
(0.2%) had three cycles. Therefore the whole patient popu-
lation received 1851 treatment cycles with rhEGF.
The main demographic characteristics are shown in
Table 1. Females, white colored, and diabetes type 2 were
predominant. Patients older than 75 years were 248 (14%).
The main co-morbidities were hypertension, ischemic car-
diopathy, previous DFU, and amputations. Ulcers were
mostly advanced (82% Wagner’s grades 3–5). Ischemic le-
sions were 34% diagnosed clinically and 9% by ABI. Simple
lesions (mainly on the toes) were the most frequent.
Treatment compliance
There were some treatment schedule deviations according
to doctors’ decisions: 267 Wagner’s grade 1, 2, or 5 ulcers
(15% of all lesions) were treated as off-label indications;
281 ischemic lesions (36%) were treated with the 25 μg
dose; 50 lesions were treated with both doses, considered
as 75 μg for the analyses; the three tpw schedule was not
followed strictly (see next paragraph); 48 treatment cycles
comprised more than 24 injections.
The 75 μg dose was given more frequently to Wagner’s
grades 3–5 ulcers (61%) than to less severe cases (53%)
and to patients with ischemia (64%) than without it (54%).
The thrice weekly regime was the most frequently used.
However, some cases were treated daily (9%) or less than
three tpw (14%). The median number of infiltrations was
10 (range 1–47). The median total exposure to rhEGF was
500 μg (range 25–3825).
Interruptions occurred in 462 treatment cycles (25%).
The causes were: voluntary abandon in 200 (10.8%)
cases; worsening of the lesion in 207 (11.2%); local
hypergranulation in 16 (0.9%), and other AE in 39
(2.1%).
Granulation
Complete granulation was achieved in 76% of the ulcers at
the end of treatment (Table 2). This favorable response
was more likely to occur in patients without clinical mani-
festations of ischemia. The other variables with significant
enhancing influence on the granulation outcome in bivari-
ate analyses were age ≤ 75 years better than older (78% vs.
Table 1 Clinical and demographical characteristics of the
patients or ulcers
Characteristics Results
(N = 1788 patients)
Age (years): median ± QR (minimum; maximum) 65.0 ± 14.0 (19; 98)
Gender: masculine/feminine (% feminine) 825/963 (53.9%)




Diabetes mellitus: type 1/type 2
(% type 2) (47 missing)
379/1362 (76.2%)
Smokers (6 missing) 368 (20.6%)
Arterial hypertension (4 missing) 1085 (60.7%)
Ischemic cardiopathy (9 missing) 411 (23.0%)
Antecedents of foot ulcers 662 (37.0%)
Antecedents of amputations 420 (23.5%)
N = 1835 ulcers
Etiology of the ulcer (1 missing)
Ischemic 790 (43.1%)






Wagner’s classification (83 missing)
Grade 1 26 (1.4%)
Grade 2 228 (12.4%)
Grade 3 981 (53.5%)
Grade 4 504 (27.5%)
Grade 5 13 (0.7%)
Yera-Alos et al. BMC Pharmacology and Toxicology 2013, 14:44 Page 4 of 11
http://www.biomedcentral.com/2050-6511/14/4459%), non-smoker (77% vs. 68%), three tpw schedule bet-
ter than <3 tpw (78% vs. 65%), non-calcaneus location
(77% vs. 66%), non-history of hypertension (79% vs. 73%),
non-history of ischemic cardiopathy (78% vs. 66%), and
the 25 μg dose (81% vs. 72%). In a multivariate, logistic re-
gression model granulation response was favored by non-
ischemia (OR: 3.6; 95% CI: 2.8-4.7), non-smoking (1.3;
1.01–1.8), age (1.02; 1.01–1.03, for each younger year),
three tpw schedule (1.9; 1.4–2.7), and the 25 μg dose (1.6;
1.2–2.0). The healthcare level, gender, ethnic group, and
Wagner’s classification were not significantly related to
the granulation outcome. The time-to-complete granula-
tion differed significantly between non-ischemic and is-
chemic lesions (log-rank test; p < 0.001).
Amputations
At the end of treatment 214 patients required 220 am-
putations (12%) (Table 2); 23 of them were disarticula-
tions, 26 transmetatarsal and 171 major amputations
(9.3% of the lesions). Ischemic ulcers caused more am-
putations. Most of the amputations (85%) were in caseswith Wagner’s 3–5 ulcers. Calcaneus location of the
ulcers was also an unfavorable factor for the amputation
outcome (18.5% vs. 11.0% in non-calcaneus ulcers).
Smoking habit (17% vs. 11% in non-smokers) and history
of previous amputation (15% vs. 11%) conditioned a
higher amputation rate too.
Adverse events
A total of 4171 AE were reported (70 different types) in
46% (856/1851) of the treatment cycles in 838 subjects
(47%). The AE occurring in more than 1% of the patients
and the maximal number of repetitions of the event in any
subject are summarized in Table 3. Pain and burning sen-
sation at the administration site, shivering and chills ac-
count for 87% of all the AE reported. Their frequency
decreased as the treatment continued: from more than
14% in the first application to less than 2% after 40 days.
More than 85% of the events were mild or moderate and
easily manageable. Except for local infection, all common
AE were more frequent with the 75 μg dose. The rate of
local infection as an AE (4%) was not dependent on the
baseline infection status of the ulcer (Table 4).
The 31 SAE reported are shown in Table 5. Two of
them (ketoacidosis and gastroenterocolitis) were unre-
lated to the treatment. The other 29 were classified as
conditional or possible, since there was a temporal rela-
tion with treatment but there are alternative explana-
tions to the clinical findings. Local infection accounted
for 32% of the SAE and cardiovascular syndromes for 14
SAE. Thirteen of the latter patients had antecedent of
cardiovascular disease (hypertension, ischemic cardiopa-
thy, or arrhythmia).
The benefit/risk ratio is presented in Figure 1. The odds
for benefit were larger than for risk (Bayes Factor = 5.4;
difference between probabilities: 61%; 95% CI: 59%–64%).Follow-up: wound closure
Post-treatment follow-up information was obtained from
1620 subjects (91%) with 1659 ulcers, at least once dur-
ing the 4 years after the end of treatment. The follow-up
period (median: 1.2; maximum 4.2 years) comprised
2270.6 years-person. The baseline and demographic
characteristics of the followed-up subjects do not differ
from the whole patient population (data not shown).
Complete ulcer re-epithelization was achieved in 55% of
all the lesions (“intention-to-treat” evaluation), 61% of
those evaluated (Table 2). In a logistic regression model
significant positive influence on this outcome was shown
by: non-ischemic etiology (OR: 2.1; 95% CI: 1.6–2.6), age
(1.012; 1.002–1.022, for each younger year), and not-
history of amputation before treatment (1.7; 1.3–2.1).
Relapses occurred in 5% person-years, regardless of the
ulcer etiology or other characteristics (Table 2).
Table 2 Lesion response to treatment according to pathogeny
Ischemic Non-ischemic Total
Complete granulation 486/790 905/1044 1392/1835
% 61.5 86.7 75.9
(95% CI) (58.1; 64.9) (84.6; 88.7) (73.9; 77.8)
Weeks to complete granulation median (95% CI) 6 (5.6; 6.3) 4 (3.8; 4.2) 5 (4.8; 5.2)
Healing 371/742 641/916 1012/1659
Evaluated (“per protocol”) % 50.0 69.9 61.0
(95% CI) (48.1; 54.9) (66.9; 73.3) (58.2; 62.9)
Included (“intention-to-treat”) % 47.0 61.4 55.1
(95% CI) (43.4; 50.4) (58.4; 64.4) (52.9; 57.4)
Relapses: (years-person of follow- up) 26/333 (561) 49/584 (927) 75/917 (1488)
Rate per year (95% CI) 4.6 (2.9; 6.4) 5.3 (3.8; 6.7) 5.0 (3.9; 6.2)
Amputations during treatment 180/790 40/1044 220/1835
% 22.8 3.8 12.0
(95% CI) (19.9; 25.7) (2.7; 5.0) (10.5; 13.5)
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During treatment or follow-up 352 patients (20%) died.
Table 6 lists the causes of death. The most frequent were
cardiovascular disorders (41.8%); among them acute
myocardial infarct and ischemic cardiopathy. Diabetes it-
self and its complications (renal disease and others) rep-
resented 17%, and tumors caused 8% of the deceases. A
Cox-regression yielded that the variables with significant
unfavorable influence on survival were (HR; 95% CI): is-
chemic etiology (1.4; 1.1–1.8), history of ischemic cardi-
opathy (1.3; 1.01–1.6), and older age (1.03; 1.01–1.04 per
year increment), whereas ulcer healing showed a signifi-
cant protective effect (0.25; 0.19–0.31). Amputation after
treatment had an inverse lineal correlation with healing.
Figure 2 illustrates the effects of healing, etiology, and
amputation on survival through the corresponding
Kaplan-Meier plots.Table 3 Frequent adverse events (> 1.0%)





Pain at the administration site 402 21.7 24




Chills 171 9.2 16
Local infection 70 3.8 4
Fever 42 2.3 7
Ulcer worsening* 30 1.6 2
Vomits 25 1.4 10
*:Reported by the doctors as adverse events. In fact, worsening of the ulcer as
a therapeutic failure occurred in 209 cycles (11.3%).During the follow-up 42 subjects were identified with
neoplasia, not diagnosed before treatment. None of them
was on the rhEGF treated region. Locations were: breast
(11), colon (5), prostate (4), uterus (4), bladder (2), lung
(3), peritoneum (2), and skin basal cell, rectum, endo-
metrium, stomach, fibrosarcoma, pancreas, kidney, phar-
ynx, spinal column, mouth, and not specified, one each.
Cancer was not related to the extent of exposure to
rhEGF treatment: all these patients had received one
treatment cycles; the average exposure was 535 μg of
rhEGF (range: 75–2100 μg).
Discussion
The postmarketing surveillance covered all the Angiology
wards that manage DFU in Cuba and some primary care
units that have incorporated this drug as part of the dia-
betic patients integral care program. The demographic
and baseline characteristics of the subjects parallel those
of people with DFU that took part in the clinical trials
with this procedure [3-7]: predominantly diabetes type 2,
median age 65 years, approximately equal gender distribu-
tion, high proportions of hypertension, ischemic cardiopa-
thy, and previous ulcers, as well as the ethnic distributionTable 4 Local infection as an adverse event vs. baseline
Occurrence of local infection
as adverse event Total
Yes No
Local infection as baseline
Yes 52 1270 1322
No 15 358 373
Total 67 1628 1695
Information on baseline infection was missing in one subject with local
infection as adverse event and in 90 subjects without it. The OR was 0.98;
95% CI: 0.54–1.76.
Table 5 Serious adverse events
Motive for seriousness Events N %*
Caused death Acute myocardial infarct 5
Sudden cardiac death 2
Acute pulmonary edema 2
Ventricular fibrillation 1
Uncompensated heart insufficiency 1
Ischemic stroke 1
Acute respiratory failure 1
Acute gastroenterocolitis 1
Diabetic ketoacidosis-septic shock 1
Subtotal 15 0.8%
Endangered life Acute pulmonary edema 2





Prolonged hospitalization Local infection 4 0.2%
Produced disability Local infection 5 0.3%
TOTAL 31 1.7%
*Percent calculated from 1851 treatment cycles.
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hypercholesterolemia, arterial hypertension and ische-
mic cardiopathy have been reported in other settings
[12] too. Nearly half of the subjects had ischemic ul-
cers, mostly Wagner’s grades 3–4, which singularizes
the application of intralesional hrEGF from other pro-
cedures that are mainly indicated in less advancedFigure 1 Risk-benefit analysis. Given p(x | benefit) by the
probability distribution function for benefit (complete granulation)
and p(x | risk) by the probability distribution function for risk
(moderate and severe adverse events or amputation) then the Bayes
Factor (Bbr) is: Bbr ¼ pðx jbenefitÞp x riskÞjð representing a summary of the
evidence provided by the data in favor of benefit (red), as opposed
to risk (blue). A value larger than 1 means a favorable benefit-risk
ratio. In this case: Bayes factor = 5.4; difference between probabilities:
61% (95% CI: 59%–64%).lesions [13]. Calcaneus ulcers were not excluded,
which is also an unfavorable condition [14].
Some deviations from the labeled pattern of hrEGF ap-
plication were seen, which were due to doctors’ prefer-
ence, according to their judgment of the patient’s
evolution. In some cases, ambulatory patients could not
attend all the visits. The dose deviations were also deter-
mined, eventually, by product availability at a given mo-
ment. The off-label use of medicaments, particularly
biologics, is not a seldom practice in many settings as
part of the common medical practice [15,16].
Treatment interruptions were mainly due to failure that
determined amputation mostly in ischemic, Wagner’s 3–5
lesions. Very few were because of patients’ intolerance (AE
or voluntary abandonments). Hypergranulation is note-
worthy since it is due to the same mechanism of healing
enhancement. It was easily controlled by tissue excess re-
moval and there is no information of related sequels, such
as hypertrophic scars or keloids.
The results of the previous clinical trials with
intralesional hrEGF (79.4% granulation in 296 patients;
95% CI: 74.8–84.0%) were confirmed in this study. The re-
epithelization rate found falls within the pooled analysis of
the clinical trials too: 59.2%; 95% CI: 53.4– 64.5% [3].
Granulation response showed good predictive value for
final healing in this series [17]. The relapse rate (5% year-
persons) is better than reported [18,19]. For example,
Boulton et al. [20] refer an estimate of 50–70% for the UK
and 34% after one year follow-up in other series. The fact
that postmarketing data confirm the results of the clinical
trials is an important feature that endorses the use of
intralesional rhEGF in medical practice for the treatment
of advanced DFU. Topical EGF [21,22] or other growth
factors [23,24] have been reported in smaller and/or less
advanced ulcers. However, there is scarce information on
their effectiveness in regular medical practice or have not
fulfilled the expectations raised from clinical trials [25].
The main variables with influence on the treatment ef-
fectiveness, both for granulation and re-epithelization,
were ischemia and age, which are well-known adverse
prognosis factor for ulcer healing [26]. However, the
granulation and healing rates attained indicate that the ef-
fect of the product is evident in ischemic patients too. Is-
chemia was considered when ABI < 0.75 or clinically. The
ABI cutoff for ischemia varies among different guidelines,
from 0.7 [27,28] to 0.9 [29]. Consequently, 40 subjects
(85% granulation; 80% re-epithelization) classified as non-
ischemic in this work would fall into a “mild” ischemia
category (with scarce clinical expose) according to other
thresholds. This supports the notion that the product is
also effective in patients with impaired blood supply.
Although this work did not include a non-treated control
group to measure the impact of the treatment on amputa-
tion rate, other independent investigations in additional
Table 6 Causes of death in diabetic foot ulcer patients treated with intralesional hrEGF
Cause Number Percent of all deaths Rate (per 100 person-years)
Cardiovascular disorders 145 41.2% 6.38%
Acute myocardial infarct 37 10.5% 1.63%
Stroke and its sequels 33 9.4% 1.45%
Ischemic cardiopathy 29 8.2% 1.28%
Cardiac failure 18 5.1% 0.79%
Hypertensive cardiac disease 9 2.6% 0.40%
Other: peripheral angiopathy (5); acute pulmonary edema (4); cardiac arrhythmias
(4); cardiac arrest and cardiogenic shock (3); generalized atherosclerosis;
non specified (2); abdominal aorta aneurism rupture (1)
19 5.4% 0.84%
Other complications of diabetes 60 17.0% 2.64%
Diabetic coma 6 1.7% 0.26%
Diabetes mellitus with renal complications 30 8.5% 1.32%
Diabetes mellitus with other complications 13 3.7% 0.57%
Diabetic foot 11 3.1% 0.48%
Respiratory disorders 53 15.1% 2.33%
Pneumonia and bronchopneumonia 49 13.9% 2.16%
Acute respiratory insufficiency 4 1.1% 0.18%
Neoplasia: breast (8); prostate (3); colon (4); bladder (2); lung (3); peritoneum
(2); pancreas (1); kidney (1); pharynx (1); spinal column (1); mouth
(1); tumor of unknown behavior, encephalus, suptratentorial (1)
28 8.0% 1.23%
Peripheral venous thrombosis and thromboembolism 12 3.4% 0.53%
Amputations and other surgical complications 12 3.4% 0.53%
Other causes: sepsis (8); upper digestive bleeding (4); gastroenteritis (2); liver cirrhosis
(2); rheumatoid arthritis (1); viral encephalitis (not specified) (1); multiorgan failure
(1); alcoholic hepatitis (1); prostate hyperplasia (1); accidents and traumatisms




(From the national death certificate database).
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Acosta et al. found a major amputation rate reduction from
26.7% to 8.3% when intralesional rhEGF was added to con-
ventional standard care [30]. García-Herrera et al. report a
43.1% to 8.1% major amputation rate reduction [31]. These
data are consistent with the 9.2% major amputation rate
found in the present work.
The most frequently observed AE such as pain and
burning sensation at the injection site, shivering, chills,
and local infection coincide with the reported intralesional
hrEGF safety profile [3-7].
Local infection is one of the most fearsome AE because
it frequently leads to amputation. Approximately 60% of
amputations are preceded by infected ulcers [32]. Local in-
fection was classified with “possible” causality relationship
with the treatment. This is difficult to evaluate since most
of these ulcers were infected at baseline. This diagnosis
was defined by signs such as edema, ulcer border redness,
and secretion. Heberprot P® labeling says that these signsshould be cleared (antibiotics, debridement) before the
product is applied. Even though, a negative culture is
never obtained. It is unlikely that the injection procedure
contributes to spread any subclinical infection as shown
by the fact that the occurrence of this AE was not associ-
ated to the baseline infection of the ulcer.
There is not enough information to relate cardiovascu-
lar AE and deaths to the treatment, since the patients
have frequent antecedents of cardiovascular diseases.
The relationship of diabetes and cardiovascular diseases
is well known, moreover if DFU is present [33,34]. In
data from the national death certificate database and the
Annual Health Report [35] for 2007–2010, the death
rates due to these causes in people with diabetes among
the three main causes of death in the certificate double
that of the general population. This death profile agrees
with the literature for DFU patients [36,37].
A particular concern on the use of growth factors is
the possibility of development or stimulation of a pre-
AB
C
Figure 2 Kaplan-Meier curves for survival time according to A) whether the ulcer healed or not; B) ulcer etiology or C) whether the
affected limb was amputated or not.
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http://www.biomedcentral.com/2050-6511/14/44existing malignancy. Contrary to PDGF, EGF cannot ini-
tiate malignant transformation [38] and results with EGF
in experimental models have not demonstrated tumor
promotion consistently [3,39]. Diabetes is a known can-
cer risk boosting condition [40-43]. The data do not
support any cancer promotion by rhEGF treatment.Giovannucci et al. discuss the possible mechanisms
of the diabetes-cancer association, either by common
risk factors or specific mechanisms in diabetes metabolism
and management [44]. This aspect has to be further
investigated and followed in the product risk-management
program.
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In summary this postmarketing, prospective study is con-
sistent with earlier findings from exploratory and con-
firmatory clinical trials, while extending the data to a
larger clinical setting. The positive findings, related to the
clinical evolution of the patients treated at secondary and
primary Cuban healthcare levels, suggest a relevant role of
this drug in the treatment of DFUs. Further clinical re-
search and post-marketing information from other coun-
tries should enrich the evidence shown in this paper.
Appendix
(Cuban Group for the Introduction of Heberprot P in
Diabetic Foot Ulcers)
Patient recruitment, treatment and follow-up.
Health Unit, Province (number of treatment cycles
performed), investigators: “Camilo Cienfuegos” Hospital,
Sancti Spíritus (211): Regla Soto-Águila (province coordin-
ator), Pablo Sánchez Pentón, Irelio Borroto Carpio, Reidel
Veloso, Yanet Hernández, Ana Tavio Reyes, Mayilé Gómez,
Liliam Moreno Perera; “Gustavo Aldereguía Lima” Hos-
pital, Cienfuegos (154): Ivonne Marrero Rodríguez, Belkis
Calaña González Posada, Ivette García, Mabel Medina,
Nancy Ramírez, Sahily González Acosta, Yadira Alonso,
Javier Borrego; “Abel Santamaría” Hospital, Pinar del Río
(128): Martha Moreira Martínez, Aida Hernández, Antonio
Díaz Díaz, Agustina Gómez García Yanet Crespo, Etty
Chirolde, Laureano Peña Bazant Pérez Jose Ortega Baez,
Ana Lidia Hernández Méndez; “Arnaldo Milián” Hospital,
Villa Clara (101): Teresita Fleito Castex, Felicia García,
Seco, Angel Alfaro, Cecilio González Benavidez; “Lucía
Iñiguez” Hospital, Holguín (99): Armando González,
Eneida Caraballosa, Esther Peña, Isel Sánchez Mirna Enel
Pérez Muñoz; “Carlos M. de Céspedes” Hospital, Granma
(95): Francisco Vázquez, José Ortega, Juan Planas Brooks,
Juan Carrazona, Eberto Caravana; “Antonio Luaces Iraola”
Hospital, Ciego de Ávila (87): José Hernández Cañete,
Mislene Álvarez Hernández, Xiomara Herrera, Jorge
Herrera Zamora; “Manuel Ascunce” Hospital, Camagüey
(84): Ariel Hernández Varela, Yanor Agüero, Fidel Rivero
Fernández, Raúl Romay Boitrago, Jorge Luis Valdez, Nicolás
Socarras, Pedro Vejerano, Ramón Bentrogo, Misleidis
González Cedeño, Nelina Morales, Odalis Escalante; “José
R. López Tabranes” Hospital, Matanzas (77): Edel Fleitas
Pérez, Leydis Hernández Rodríguez, Jaqueline Ramos
Serpa, Martha Jiménez, Arístides García Herrera, Elizabeth
Cao, Isis de la Caridad Abreu Jiménez, Daymar Bom Pérez,
Yadira García; “Agostinho Neto” Hospital, Guantánamo
(72): Zulema Mena, Georgina Grave de Peralta, Vladimir
Sarrión; “Ernesto Guevara” Hospital, Las Tunas (58):
Dianelis González, Zulema Elliot Pérez, José Luis Solis, José
Luis Rivero Miranda, José Pablo Ponce; “Ambrosio Grillo”
Hospital, Santiago de Cuba (57): Emilio Goulet, Lisandra
Betancourt, Alina Echevarría, Jorge Lockhant; “EnriqueCabrera” Hospital, Havana (44): Heriberto Artaza Sans,
Sandra González Pelegrí, Angela Blanco Díaz, Natalia Poll
Marrón, Evaristo Vargas Machirán, Eduardo Atencio Soriol,
Pedro Goicochea Díaz; “Julio Arestegui” Hospital, Matanzas
(37): Leitter Pérez, Juan Díaz; “Julio Trigo” Hospital,
Havana (36): Reinaldo Martínez Garrido; “Saturnino Lora”
Hospital, Santiago de Cuba (36): Natacha Sancho Sueto,
Arelis Frómeta, David Díaz, Hever Viguera, Mayelin
Sabourit; “Amalia Simoni” Hospital, Camagüey (35): Alberto
Álvarez Varona, Jorge Gómez , Gustavo Pérez Hechevarría,
Denny González, Victor Alfonso; “Guillermo Domínguez”
Hospital, Las Tunas (29): Wilber Velázquez Chacón;
“Calixto García” Hospital, Havana (26): Osmel Castillo,
Aimeé Rodríguez Hernández, María Campos, Remberto
García, Joaquín David Liziaga Vázquez, Julio César Nuñez
Vázquez; “Joaquín Castillo” Hospital, Santiago de Cuba
(26): Bencay Joa Liranza; Octavio de la Concepción Hos-
pital, Guantánamo (26): Arturo Pons; “Celia Sánchez” Hos-
pital, Granma (24): Odelaisys Hernández Saborit, Sergio
Fernández; “Victoria de Girón” Polyclinic, Santiago de
Cuba (23): Carlos Calderón, Orlando San Pedro; “Carlos
Font” Hospital, Holguín (22): Tamara Pérez; “Roberto
Rodríguez” Hospital, Ciego de Ávila (22): Elier del Castillo,
Jorge Morales Florat; “Alcides Pino” Polyclinic, Holguín
(20): María Antonia Rodríguez, Tania García; “Mártires de
Mayarí” Hospital, Holguín (19): Isabel Carrasco, Eneida
Caraballosa; Military Hospital, Holguín (18): Pedro Matos
García, Olides Cobas Díaz, Daniel Rodríguez Curí; “Diez
de Octubre” Hospital, Havana (17): Deysi Acosta Lapera,
Héctor Chivas, Manuel Hernández Rivero; National Insti-
tute for Angiology and Vascular Surgery, Havana (17): José
Fernández Montequín , Calixto Valdez Pérez, José Llanes
Barrios, Williams Savingne Gutierrez, Neobalis Franco
Pérez, Daniel Reynaldo Concepción; “Comandante Manuel
Fajardo” Accommodation, Havana (13): Reyna Lourdes
Morejón Vega; “Manuel Fajardo” Hospital, Havana (12):
Milagros Romero Gamboa, Máximo Sander López;
“Orlando Pantoja” Hospital, Santiago de Cuba (12): Raúl
Mesa; “Máximo Gómez” Polyclinic, Granma (12): Rafaela
Rondón; “Ciro Redondo” Hospital, Artemisa (11): Odelaysis
Hernández Saborí; “Aleida Fernández” Hospital, Mayabeque
(11): Pedro González, Vicente Vega Mederos; “Comandante
Pinares” Hospital, Artemisa (8): José Ortega Baez; “Martha
Abreu” Polyclinic, Villa Clara (8): Juan Miguel García
Velázquez; “XXX Anniversary” Polyclinic, Villa Clara (7):
Juan Miguel García Velázquez; “Edor Reyes” Polyclinic,
Granma (6): Salvador Oliva; “Roberto Fleites” Polyclinic,
Villa Clara (6): Juan Miguel García Velázquez; “Miguel
Enriquez” Hospital, Havana (5): Luis Olivera Baez, Justa
Peñalver; “Santa Cruz del Sur” Hospital, Camagüey (5): Luis
Gustavo Cisneros; Banes Hospital, Holguín (4): Antonio
Ricardo García; “XXX Aniversario” Hospital, Villa Clara (4):
Juan Miguel García Velázquez; Camilo Cienfuegos Poly-
clinic, Havana (3): Carmen Luisa Ramos; “Manuel A
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http://www.biomedcentral.com/2050-6511/14/44Varona” Polyclinic, Camagüey (3): Esteban Lopez; “Tamara
Bunke” Polyclinic, Holguín (3): Luis Aguilar; “Gustavo
Aldereguía” Hospital, Holguín (2): Manuel Balán; “Juan
Bruno Zayas” Hospital, Santiago de Cuba (2): Rolando
Castillo; “San Luis” Polyclinic, Pinar del Río (2): Aida Rosa
Hernández; “XX Anniversary” Polyclinic, Villa Clara (2):
Juan Miguel García Velázquez; “19 de Abril” Polyclinic,
Havana (2): Reyna Lourdes Morejón Vega; “Wajay” Poly-
clinic, Havana (2): Angela Blanco Díaz; “Colón” Hospital,
Matanzas (1): Alejandro Piedra-Fita Tejeda; “Mario Muñoz”
Hospital, Matanzas (1): Maylin Torres; “Ramón Pando
Ferrer” Polyclinic, Villa Clara (1): Juan Miguel García
Velázquez; “Santa Clara” Polyclinic, Villa Clara (1): Juan
Miguel García Velázquez; “Isabel Rubio” Polyclinic, Pinar
del Río (1): Aida Rosa Hernández; “Raúl Sanchez” Poly-
clinic, Pinar del Río (1). Aida Rosa Hernández.
Monitoring, data management, and analyses.
Center for the Development of Pharmacoepidemiology:
Isis Belkis Yera Alós, Liuba Carbonell Alonso, Julián Pérez
Peña, Francisco Debesa García, Alina Alvarez Crespo,
Ismary Alfonso Orta, Giset Jiménez López, Jenny Ávila
Pérez, Ana García Milián, Aleida Díaz Hernández; National
Pharmacoepidemiology Network: Yumara Díaz Castro
(Pinar del Río), Gustavo Rodríguez (Artemisa–Mayabeque),
Deborah Rodríguez Piñeiro (Havana), Adis Martín (Havana),
Lia Mónica Bravo (Havana), Loida Báez (Havana), Armando
Morri (Havana), Leydis Santos Muñoz (Matanzas), Miraida
Baute (Cienfuegos), Luis Orlando Rico Martell (Ciego de
Ávila), Orlando René Águila González (Villa Clara), Betania
Rodríguez (Sancti Spíritus), Natacha Caballero (Camagüey),
Soraida García (Las Tunas), Maria Elena Fernández Tablada
(Holguín), Gloria Zaldivar (Holguín), Zayda Herrera López
(Holguín), Yeraldis Ramírez Calzadilla (Granma), Sheila
Tamayo (Santiago de Cuba), Yudeisi Trabanca Beltrán
(Guantánamo); Center for Genetic Engineering and Biotech-
nology: Ernesto López Mola, Angela Tuero Iglesias, Carmen
Valenzuela Silva, Jorge Berlanga Acosta, Miriela Gil Mena,
Ricardo Silva Rodríguez, Marianela García Siverio, Francisco
Hernández Bernal, Elizeth García Iglesias, Leovaldo Álvarez
Falcón, María Dolores Castro Santana, Rafael Ibargollín
Ulloa, Luis Herrera Martínez, Pedro Antonio López Saura.
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